What is the appropriate use, dosing, and monitoring of montelukast for asthma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Montelukast for Asthma

Montelukast is an appropriate alternative therapy for mild persistent asthma in patients unable or unwilling to use inhaled corticosteroids, but inhaled corticosteroids remain the preferred first-line treatment due to superior efficacy in controlling symptoms and preventing exacerbations. 1

Positioning in Asthma Treatment

Mild Persistent Asthma (Step 2)

  • Preferred treatment: Low-dose inhaled corticosteroid (ICS)
  • Alternative treatment: Montelukast is listed as an acceptable alternative alongside cromolyn, nedocromil, or theophylline 1
  • Key advantage: Once-daily oral administration provides ease of use and high compliance rates 1
  • Important caveat: While montelukast improves asthma control compared to placebo, inhaled corticosteroids are superior for controlling daytime and nighttime symptoms 2

Moderate Persistent Asthma (Step 3-4)

  • Preferred approach: Low-to-medium dose ICS plus long-acting beta-agonist (LABA)
  • Alternative approach: Low-to-medium dose ICS plus montelukast 1, 3
  • Evidence limitation: Studies of ICS plus montelukast combination are limited, particularly in children under 12 years 3
  • Critical finding: Adding montelukast as a third medication to medium-to-high dose ICS plus LABA in severe persistent asthma showed no additional benefit 3

Dosing by Age

FDA-approved dosing 4:

  • Ages 1-5 years: 4 mg chewable tablet once daily
  • Ages 6-14 years: 5 mg chewable tablet once daily
  • Ages 15 years and older: 10 mg tablet once daily

Timing: Administer in the evening for asthma (morning or evening acceptable for allergic rhinitis) 4

Administration: Can be taken without regard to food 4

Clinical Efficacy Data

Pediatric Evidence

The PACT trial 2 provides the most definitive pediatric data:

  • 285 children (ages 6-14) with mild-to-moderate persistent asthma
  • Fluticasone monotherapy gained 42 more asthma control days per year compared to montelukast (p=0.004)
  • Number needed to treat: approximately 7 children need fluticasone instead of montelukast to achieve one additional treatment response
  • Growth rates were similar across all groups (no significant difference)

Adult Evidence

In adults with mild-to-moderate persistent asthma 4:

  • Montelukast reduced "as-needed" beta-agonist use by 26.1% versus 4.6% for placebo
  • Reduced nocturnal awakenings by 34% versus 15% for placebo
  • Improved FEV1 by mean 7.49% versus placebo

Comparative Effectiveness

Montelukast versus ICS 5, 6:

  • Meta-analysis shows ICS superior for controlling symptoms, especially nighttime symptoms
  • Montelukast inferior to ICS (OR 1.63) and ICS plus LABA (OR 3.94) for preventing exacerbations 6

Special Populations and Indications

Young Children (2-5 years)

  • Limited efficacy data in this age group 1, 3
  • FDA approval based primarily on safety data and pharmacokinetic extrapolation 3
  • May reduce exacerbations in intermittent asthma associated with viral infections 7

Add-on Therapy

  • When low-dose ICS insufficient: LABA is preferred add-on therapy over montelukast 8
  • Montelukast may benefit the small subset who respond better to it than LABA 8

Concomitant Allergic Rhinitis

  • Montelukast approved for both asthma and allergic rhinitis 9
  • Particularly attractive option when treating combined upper and lower airway disease 9
  • May be preferred in families with "steroid-phobia" 9

Critical Safety Warning

The FDA issued a Boxed Warning for montelukast in March 2020 10 regarding neuropsychiatric events including:

  • Agitation
  • Depression
  • Sleep disturbances
  • Suicidal thoughts and behavior

Clinical implication: Reserve montelukast for patients where alternative treatments are inadequate or not tolerated. Counsel patients and families about these risks.

Monitoring

No routine laboratory monitoring required 4

Clinical monitoring should assess:

  • Symptom control (daytime and nighttime)
  • Rescue inhaler use (>2 days/week indicates inadequate control)
  • Asthma exacerbations
  • Neuropsychiatric symptoms (given FDA warning)

Response assessment: Conduct an N-of-1 trial approach 8:

  • Trial montelukast for 4-6 weeks
  • Objectively assess response using symptom scores, peak flow, and rescue medication use
  • Discontinue if no convincing response - do not leave patients on ineffective therapy 8

Common Pitfalls

  1. Overprescribing: Clinically, more children receive montelukast than evidence suggests will respond 8. Always attempt ICS first unless contraindicated.

  2. Continuing without response: No biomarker predicts montelukast response 8. Must perform clinical trial and discontinue if ineffective.

  3. Using as monotherapy in moderate-severe asthma: Montelukast alone is insufficient for moderate-to-severe disease 1, 6.

  4. Adding as third-line agent: No benefit when added to ICS plus LABA 3.

  5. Ignoring neuropsychiatric risks: The 2020 FDA Boxed Warning necessitates careful patient selection and monitoring 10.

References

Research

Montelukast in paediatric asthma and allergic rhinitis: a systematic review and meta-analysis.

European respiratory review : an official journal of the European Respiratory Society, 2023

Research

Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma.

American journal of respiratory and critical care medicine, 2005

Guideline

the diagnosis and management of rhinitis: an updated practice parameter.

Journal of Allergy and Clinical Immunology, 2008

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.